Genome-wide association studies (GWAS) have been extensively used to study common complex diseases such as coronary artery disease (CAD), revealing 153 suggestive CAD loci, of which at least 46 have been validated as having genome-wide significance. However, these loci collectively explain <10% of the genetic variance in CAD. Thus, we must address the key question of what factors constitute the remaining 90% of CAD heritability. We review possible limitations of GWAS, and contextually consider some candidate CAD loci identified by this method. Looking ahead, we propose systems genetics as a complementary approach to unlocking the CAD heritability and etiology. Systems genetics builds network models of relevant molecular processes by combining genetic and genomic datasets to ultimately identify key "drivers" of disease. By leveraging systems-based genetic approaches, we can help reveal the full genetic basis of common complex disorders, enabling novel diagnostic and therapeutic opportunities. (J Am Coll Cardiol 2015;65:830-45) 
H eritability is the proportion of observed differences in a trait among individuals that are due to genetic differences chiefly believed to be identifiable in DNA. In addition, environmental factors including random chance also combine with genetic factors to contribute to traits, like phenotypes of a disease. Traditionally, genetic and environmental factors have been viewed and studied largely as 2 independent entities contributing to disease. In reality, the interaction of environmental and genetic factors to cause a trait or a disease is significant. In fact, the presence or absence of an environmental factor may determine whether or not a genetic factor will contribute to disease. Genomewide association studies (GWAS) that arose from the successes of using family and linkage studies to understand causative variants for rare disorders have been successful to define several hundred
INTRODUCTION GENETICS OF RARE SINGLE-GENE DISORDERS-THE FOUNDATIONS OF THE SEARCH FOR HERITABILITY
OF COMMON DISORDERS. The heritability of traits between generations is principally carried in deoxyribonucleic acid (DNA), mainly as single nucleotide polymorphisms (SNPs), insertions, deletions, or copy number variants. Another type of heritability, believed to be independent of DNA (1, 2) , is carried by epigenetic mechanisms, which are attributed with inducing major shifts in DNA transcription (3) . Epigenetics is not a topic of this paper, but has been reviewed extensively elsewhere (4) . In the case of rare disorders, most carriers of 1 or more highly penetrant risk variant develop the disease at some point ( Figure 1A) . However, it is also common that some persons carrying a potentially causative variant will not develop that disorder; thus, the penetrance is typically <100%. Penetrance is a time-dependent aspect of phenotypic disease expression. For example, both Huntington disease and cystic fibrosis are virtually 100% penetrant: cystic fibrosis usually soon after birth and Huntington disease by about 70 years of age. In contrast, familial breast cancer-associated mutations in the BRCA1 gene have a lifetime penetrance of 60% to 85%. That risk variants do not necessarily lead to manifest disease in all carriers has been highlighted as a possible path to identify genetic and environmental mechanisms that confer resistance to certain rare diseases (5) . Mechanisms that buffer against disease could be potential therapeutic targets.
Despite the high penetrance of disease-causing variants, rare diseases are, by definition, rare. As a result of differences in genetic ancestry, the spectrum and relative frequencies of disease-associated alleles vary among different populations. For example, cystic fibrosis is most common in populations originating from northern or western Europe (w1 in 2,000), whereas sickle-cell anemia is more common in African or Afro-Caribbean populations (w1 in 3,000). Through careful characterization of symptoms and disease phenotypes in families carrying rare disorders, the causes of nearly one-half of the estimated 7,000 single-gene disorders have been identified, mainly by using markers found at increased density across the genome and by linkage analysis in pedigrees of disease-carrying families (6) . Although these were key techniques in the discovery of highly-heritable single-gene disorders that typically only affect a limited number of biological pathways and tissues, their scope is inadequate for genetic studies of complex disorders such as atherosclerosis and CAD, where disease inheritance is blended with environmental risk factors, and causative genes are likely to be operative across several tissues (7) .
GENETICS OF COMMON COMPLEX DISORDERS-GENOME-WIDE ASSOCIATION STUDIES.
The successful identification of the genetic causes and mechanisms of many rare single-gene disorders inspired scientists to use a similar approach to study common complex disorders. Because such diseases are widespread, linkage analysis within families was not believed to be appropriate. Furthermore, it was expected (and now confirmed) that many genetic signals underlie common complex disorders, each with a relatively weak effect (e.g., odds ratio: <1.5). A study design was instead chosen that analyzed increasingly dense genomic markers in thousands of mostly unrelated individuals in case-control association studies. From these lines of argument, the GWAS design was born (8) .
One of the first GWAS of CAD came from the Wellcome Trust Case Control Consortium, which discovered that the chromosome 9 locus was associated with CAD (9) (10) (11) . Since then, 153 suggestive DNA variants associated with CAD have been discovered by GWAS, of which 46 were replicated in metaanalyses of genome-wide association (GWA) datasets (12) . These CAD-associated loci are strikingly pervasive across the population, but generally have weak effects. As recently reviewed (8) , 50% of the CADassociated variants occur in over one-half of the population, and at least 25% occur in over 75% of the population. However, each variant usually confers a minimal to modest increase in relative risk, averaging only 18% (corresponding to an odds ratio of 1.18). A common theme of recent GWAS reviews is the success of this approach, both for CAD and for other, Systems Genetics to Understand CAD more or less complex disorders, for which more than 1,000 loci have been identified (13) . Certainly, the sheer number of loci discovered, which has also led to the discovery of many previously unknown disease-causing genes, is a major success. Nevertheless, for most common complex disorders, the combined contribution of these loci to disease variation in the population is frequently <10%. Indeed, the 153 known CAD-associated variants explain <10.6% of the likely genetic variation across the population (12) .
Thus, w90% of the heritability of CAD, and of most other common complex disorders, remains unexplained by identified GWA loci, despite the inclusion of remarkably large numbers of subjects: a recent meta-analysis of several GWAS for CAD comprised 63,746 cases and 130,681 controls (12) . Although a GWAS-based approach will clearly not reveal the full extent of the heritability of CAD and other common complex disorders, more complete sequencing techniques, particularly expanded whole-exome/wholegenome sequencing (WES/WGS), typically applied to the same case-control cohorts previously used in GWAS, promise to reveal additional rare risk variants, perhaps with larger effects on heritability (14) . These results and additional refinements of the analysis of existing GWAS (14) will contribute to reducing the large fraction of missing heritability, but to what extent?
When addressing the "missing heritability" it is also reasonable to question the reliability of CAD heritability estimates. Because the overall fraction of genetic variance in CAD is less than we believe, is missing heritability largely (w90%) exaggerated?
From traditional analysis of family pedigrees in note, the indicated sigmoidal curve for rare disease development merely reflects that most biological events follow this growth pattern; it does not indicate that this true for all rare diseases. (B) The development of complex diseases, such as coronary artery disease (CAD), generally follows a sigmoidal curve, characterized by a slow initial growth phase (30 to 50 years), reaching a triggering level to enter a subsequent rapid expansion phase (10 years), and finally, a slow-down phase in which clinical symptoms manifest. Subjects in genome-wide association studies (GWAS) are more likely to be defined as cases or controls predominantly on the basis of early disease processes, rather than due to later, largely overlapping processes. As a result, the likelihood of finding risk variants with genome-wide significance is higher for disease processes active in early CAD development. (C) Given the large overlap between cases and controls, increasing dependence of environmental contexts, and the shorter duration of late disease processes, DNA variants regulating these processes are likely associated with disease at nominally-significant p values in traditional analyses of genome-wide association datasets.
twins, the range of genetic variance in CAD is between 40% and 60% (15) . Assuming 40% heritability, the 153 genome-wide significant SNPs explain 10.6% of CAD variability. Another way of assessing heritability using GWA datasets is to consider all measured SNPs (16) . When applying this "polygenic" model to the complex trait of height, 294,831 SNPs were found to explain as much as 45% of height variance (16) In the second phase, the small plaques expand rapidly, both across the arterial wall and, importantly, into the lumen of the artery, where they can compromise blood flow. The expansion phase is rapid (w10 weeks) in mice, and evidence from 14 C dating of human atherosclerotic plaques (23) suggests that it is also rapid (relative to lifespan) in humans (<10 years before clinical symptoms).
In the third and final phase, plaque biology can be ). The base of the triangle consists of risk variants associated with CAD at a level of nominal significance (p < 0.05). On the right, the likely influences of different significance levels on context dependency, penetrance, and disease are indicated. On the far right is the likely mode of discovery for testing genome-wide significance (p < 10 À8 ). DM ¼ diabetes mellitus; GWA ¼ genome-wide association;
GWES ¼ genome-wide network studies; other abbreviations as in Figure 1 .
causes an acute coronary syndrome (myocardial infarction or unstable angina) or sudden death.
GWA LOCI FOR COMMON COMPLEX DISEASES-HOW IMPORTANT ARE THEY?
Genome-wide significant loci identified by GWAS conducted for complex diseases may fail to identify central pathological processes and corresponding key DNA variants that contribute to heritability. This notion rests primarily on 3 conventions about the development and phenotypic expression of complex, relatively rare diseases ( Figures 1A and B ). Systems Genetics to Understand CAD adolescence and the early adult years). Also, as the first and longest phase of CAD development, the inclination of the curve of the slow phase will be highly decisive for how case and control subjects are defined in GWAS ( Figure 1C) . Conversely, the most significant disease-associated DNA variants, defined by comparing case and control subjects (genomewide significant variants), will likely point toward genes active in the early phase. In contrast, the late and rapid phases are driven more by disease processes that are often shared between case and control subjects (e.g., obesity, hypertension, dyslipidemia, and diabetes) and that are more influenced by environmental factors compared with the early phase.
. T h e c o n t e x t o f s h i f t i n
Thus, DNA variants affecting later CAD phases are more likely to be context-dependent. Adding to the complexity of the later phases is that they commonly involve many other parallel disease processes acting across several organs. For CAD, these organs are primarily metabolic (e.g., the liver and pancreas with diabetes, adipose tissue with obesity, or systemic immune activation). Thus, although late processes likely involve additional systemic contributions linked to context-dependent DNA variants that are unlikely to be explained by genome-wide significant loci detected by GWAS, early processes are more likely to be genetically driven and exposed to fewer confounding factors, and therefore, are more likely to contain regulatory DNA variants of genome-wide significance.
Multiple ongoing studies seek to better understand the mechanisms of the 46 genome-wide significant loci thus far identified by GWAS for CAD, and whether they relate to early or late events in CAD development In summary, considerable evidence supports the notion that genes so far identified for GWAS loci predominantly regulate early CAD development.
We expect that the extensive ongoing studies into the molecular mechanisms of the 46 confirmed GWA-defined CAD loci will shed light on this issue, as these mechanisms were sampled during open thorax surgery as described (7). Ribonucleic acid (RNA) samples were isolated from the atherosclerotic arterial wall, internal mammary artery, liver, skeletal muscle (Sklm.), subcutaneous (s.c.) and visceral fat, whole blood, and primary blood monocytes differentiated into macrophages and foam cells in vitro.
(C) Clinical endpoints. In each patient, a total of 114 clinical characteristics were screened, including the SYNTAX score (from pre-operative angiograms), which shows the clinical degree of coronary atherosclerosis. Currently, the 5-year follow-up of mortality (from CAD and other reasons) and CAD-related morbidity is being conducted.
(D) Data generation. GenomeWideSNP_6 arrays (Affymetrix) were used for genotyping DNA, and Custom-made HuRSTA-2a520709 arrays (Affymetrix) were used for gene expression profiling (STAGE) and RNA sequencing (Illumina2500, STARNET). (E) Systems genetic analysis. Gene expression and RNA sequence data are used to define groups of genes acting together in modules and networks based on coexpression similarities (17, 52, 64, 65 association datasets are integrated in the analysis of these networks to determine their load of inherited risk, which also indicates their level of causality.
(Right) Key drivers in disease-causing networks are analyzed against transcriptomic data from studies of numerous approved and experimental drugs to identify drugs that either increase or decrease the activity of genes in the network (i.e., drug repurposing; heat map indicates gene activity in a network exposed to drugs). Identified drugs can be tested in models of complex disease (e.g., mouse models). The final goal is to enable diagnosis and treatment of To decipher the relative roles of these CAD networks in individual ethnicities, 1 strategy is to examine inherited risk profiles of CAD networks for AA, EA, and HA.
For this, it is necessary to compute CAD network eQTLs for associations with CAD (risk) using GWA datasets specific to these ethnicities (12, 82, 83 ) (see part 2 in "The Role of GWAS in the Era of Systems Genetics").
Nonetheless, additional GWNS are certainly required on the basis of study designs similar to those of STAGE and STARNET, but on non-Caucasians, and preferably across the entire spectrum of complex disorders.
In this review, we suggest that we are on the verge of a new era of discovery of the genetics of CAD and other complex disorders, primarily on the basis of GWNS and GGES. We therefore strongly advocate that additional GWNS should be encouraged by funding bodies, as they hold great promise to decipher complex disease etiologies and represent an alternative route to extract further meaningful information from existing GWA datasets.
THE ROLE OF GWAS IN THE ERA OF SYSTEMS GENETICS
Although GWAS, followed by WES and WGS ("GWA datasets"), will remain fundamentally important in the search for the genetic causes of disease, we believe that integrating these datasets in GWNS provides a parallel approach for clinical studies that should help to define additional genetic regulators of CAD and other complex diseases. We anticipate that GWNS may uncover a significant portion of the missing heritability. We suspect that GWA datasets contain untapped information about the heritability of complex diseases and that, in the era of systems genetics, by integrating the analysis of GWNS with GWA datasets, we can prioritize risk variants that fail to reach genome-wide significance. With this perspective, we foresee that GWA datasets will be reutilized in at least the following 3 ways. In summary, given the shortage of new drugs reaching the market for CAD and many other complex diseases, drug repurposing, using a systems genetics approach to define new agents and novel indications for existing therapies, will be an essential path toward personalized and preventive drug therapies.
SUMMARY AND FUTURE DIRECTIONS
To answer our own question posed in the title of this paper, there is no doubt that GWAS are important in 
